RxDoctor Payments Data

Mohammad Assaf, MD

Neurology · Memphis, TNNPI 1205845468

Payments from drug & device makers

$3,294in general payments, 2019–2025

Across 91 payments — averaging $36.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Livanova USA, Inc.$2K
  • AbbVie$266
  • EMD Serono, Inc.$231
  • Eisai Inc.$218
  • Novartis$160
  • Medtronic$125
  • plus $648 from 16 others

What the payments were for

  • Speaking & faculty fees$411%
  • Travel & lodging$1,16935%
  • Food & beverage$2,00761%
  • Education$772%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,294 in reported general payments places this provider in the 50th percentile of 361 neurology providers in Tennessee.

See all neurology providers in Tennessee

Medicare billing

Part B allowed, 2024
$317,290
Medicare patients
813
Services billed
4,522

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Rebif RebidoseInterferon Beta-1a/Albumin23$281,300
Avonex Pen (4 Pack)Interferon Beta-1a17$138,230
TecfideraDimethyl Fumarate13$115,820
Dimethyl Fumarate16$60,577
NamzaricMemantine Hcl/Donepezil Hcl45$39,105
FycompaPerampanel26$31,218
Levetiracetam665$21,921
Lacosamide175$19,719
Aimovig AutoinjectorErenumab-Aooe17$12,638
Gabapentin794$11,146
BrilintaTicagrelor15$10,491
EliquisApixaban11$6,473
Memantine Hcl278$5,036
TegretolCarbamazepine24$5,004
Divalproex Sodium167$4,686

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BiogenTecfidera$62$115,82013 claims
AbbVieNamzaric$266$39,10545 claims
Eisai Inc.Fycompa$218$31,21826 claims
AstraZenecaBrilinta$77$10,49115 claims
PfizerEliquis, Dilantin$28$8,19722 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 361 neurology providers in Tennessee.

Other neurology in Memphis

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →